NO20063623L - Noytral endopeptidase (NEP) og human loselig endopeptidase (HSEP) inhibitorer for profylakse og behandling av neurodegenerative forstyrrelser - Google Patents

Noytral endopeptidase (NEP) og human loselig endopeptidase (HSEP) inhibitorer for profylakse og behandling av neurodegenerative forstyrrelser

Info

Publication number
NO20063623L
NO20063623L NO20063623A NO20063623A NO20063623L NO 20063623 L NO20063623 L NO 20063623L NO 20063623 A NO20063623 A NO 20063623A NO 20063623 A NO20063623 A NO 20063623A NO 20063623 L NO20063623 L NO 20063623L
Authority
NO
Norway
Prior art keywords
endopeptidase
hsep
nep
prophylaxis
treatment
Prior art date
Application number
NO20063623A
Other languages
English (en)
Inventor
Michael Weske
Lechoslaw A Turski
Hrissanthi Ikonomidou
Dieter Ziegler
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34796705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20063623(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20063623L publication Critical patent/NO20063623L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

Oppfinnelsen vedrører en ny anvendelse av kjente benzazepin-, benzoksazepin-, benzotiazepin-N-eddiksyre- og fosfono-substituerte benzazepinonderivater med nøytral endopeptidase (NEP) og/eller human løselige endopeptidase (hSEP) hemmende aktivitet. Forbindelsene ifølge oppfinnelsen er nyttige ved fremstilling av farmasøytiske sammensetninger for profilakse og behandling av neurodegenerative forstyrrelser. Forbindelsene ifølge oppfinnelsen er kjente fra Europeisk patenter EP 0 733 642 og EP 0 916 679, og kan beskrives ved den generelle formel (l): der symbolene har betydningene som er gitt i beskrivelsen.
NO20063623A 2004-01-12 2006-08-10 Noytral endopeptidase (NEP) og human loselig endopeptidase (HSEP) inhibitorer for profylakse og behandling av neurodegenerative forstyrrelser NO20063623L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53553804P 2004-01-12 2004-01-12
EP04100067 2004-01-12
PCT/EP2005/050075 WO2005067937A1 (en) 2004-01-12 2005-01-10 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
NO20063623L true NO20063623L (no) 2006-10-12

Family

ID=34796705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063623A NO20063623L (no) 2004-01-12 2006-08-10 Noytral endopeptidase (NEP) og human loselig endopeptidase (HSEP) inhibitorer for profylakse og behandling av neurodegenerative forstyrrelser

Country Status (22)

Country Link
EP (1) EP1706121B1 (no)
JP (1) JP4951350B2 (no)
KR (1) KR101219580B1 (no)
CN (1) CN101076339B (no)
AT (1) ATE406899T1 (no)
AU (1) AU2005205067B2 (no)
BR (1) BRPI0506750A (no)
CA (1) CA2551789C (no)
CY (1) CY1108588T1 (no)
DE (1) DE602005009487D1 (no)
DK (1) DK1706121T3 (no)
ES (1) ES2313279T3 (no)
HR (1) HRP20080611T3 (no)
IL (1) IL176456A (no)
NO (1) NO20063623L (no)
PL (1) PL1706121T3 (no)
PT (1) PT1706121E (no)
RU (1) RU2362563C2 (no)
SI (1) SI1706121T1 (no)
UA (1) UA82008C2 (no)
WO (1) WO2005067937A1 (no)
ZA (1) ZA200605549B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750510A1 (en) * 2009-01-24 2010-07-29 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
AR079059A1 (es) 2009-12-07 2011-12-21 Abbott Healthcare Products Bv Acido ((3s)-3-(((1-(((2r)-2-carboxi-4-(1-naftil) butil) ciclopentil)-carbonil) amino )-2-oxo-2,3,4,5-tetrahidro-1h-1-benzazepin-1-il) acetico cristalino, su preparacion y uso
CN106065006B (zh) * 2015-04-22 2020-06-05 深圳信立泰药业股份有限公司 一种中性内肽酶抑制剂盐晶型及其制备方法
PL424453A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
CN110590695B (zh) * 2019-10-22 2023-03-21 南华大学 苯并氮杂环类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SK15812000A3 (sk) * 1998-04-23 2001-03-12 Novartis Ag Inhibítory enzýmu na premenu endotelínu
US20020013307A1 (en) * 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6505135B2 (en) * 2001-03-13 2003-01-07 Micro Motion, Inc. Initialization algorithm for drive control in a coriolis flowmeter
SK14102003A3 (sk) * 2001-05-18 2004-08-03 Solvay Pharmaceuticals Gmbh Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul

Also Published As

Publication number Publication date
PL1706121T3 (pl) 2009-02-27
HRP20080611T3 (hr) 2008-12-31
DE602005009487D1 (de) 2008-10-16
ZA200605549B (en) 2007-12-27
SI1706121T1 (sl) 2009-02-28
RU2006129288A (ru) 2008-02-20
KR101219580B1 (ko) 2013-01-08
EP1706121B1 (en) 2008-09-03
PT1706121E (pt) 2008-12-04
EP1706121A1 (en) 2006-10-04
CA2551789C (en) 2011-05-03
IL176456A (en) 2010-03-28
ATE406899T1 (de) 2008-09-15
CN101076339A (zh) 2007-11-21
RU2362563C2 (ru) 2009-07-27
UA82008C2 (uk) 2008-02-25
CY1108588T1 (el) 2014-04-09
AU2005205067B2 (en) 2009-10-22
CN101076339B (zh) 2011-02-09
BRPI0506750A (pt) 2007-05-22
JP4951350B2 (ja) 2012-06-13
ES2313279T3 (es) 2009-03-01
CA2551789A1 (en) 2005-07-28
AU2005205067A1 (en) 2005-07-28
DK1706121T3 (da) 2009-01-05
KR20060123541A (ko) 2006-12-01
WO2005067937A1 (en) 2005-07-28
IL176456A0 (en) 2006-10-05
JP2007517834A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
GEP20125565B (en) Lactam compounds and their pharmaceutical use
WO2006011050A3 (en) Pyridine derivatives
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
MX2012001985A (es) Derivados de 3-amino-5-fenil-5,6-dihidro-2h-[1,4]oxazina.
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
HRP20041132A2 (en) 7-aryl-3, 9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
WO2006099943A8 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
WO2005040171A8 (en) Pyrazolo and imidazo-pyrimidine derivatives
IL172419A0 (en) Piperazine derivatives and methods of use
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
CY1108588T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΟΥΔΕΤΕΡΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (ΝΕΡ) ΚΑΙ ΑΝΘΡΩΠΙΝΗΣ ΔΙΑΛΥΤΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (hSEP) ΓΙΑ ΤΗΝ ΠΡΟΦΥΛΑΞΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΠΑΘΗΣΕΩΝ
NO20070089L (no) DPP-IV inhibitorer
WO2005030209A8 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
IL187001A0 (en) Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
WO2007111983A8 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
ATE518858T1 (de) Pyrroloä3,2-cüpyridinderivate und herstellungsverfahren dafür
GB0407025D0 (en) Novel compounds
TW200621773A (en) Bicyclononene derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
BDEC Board of appeal decision

Free format text: KLAGEN FORKASTES

Effective date: 20170123